Intellia Therapeutics Inc’s filing revealed that its EVP, Chief Scientific Officer Schultes Birgit C unloaded Company’s shares for reported $539.0 on Oct 01 ’25. In the deal valued at $17.38 per share,31 shares were sold. As a result of this transaction, Schultes Birgit C now holds 105,184 shares worth roughly $2.5 million.
Then, Dube Michael P sold 1,871 shares, generating $32,518 in total proceeds. Upon selling the shares at $17.38, the VP, Chief Accounting Officer now owns 55,266 shares.
Before that, CHASE WILLIAM J bought 100,000 shares. Intellia Therapeutics Inc shares valued at $1,003,000 were divested by the Director at a price of $10.03 per share. As a result of the transaction, CHASE WILLIAM J now holds 134,693 shares, worth roughly $3.2 million.
Citizens JMP upgraded its Intellia Therapeutics Inc [NTLA] rating to a Mkt outperform from a a Mkt perform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who increased its forecast for the stock in late April from “a Peer perform” to “an Outperform”. H.C. Wainwright began covering NTLA with “Buy” recommendation on March 05, 2025. JP Morgan revised its rating on February 28, 2025. It rated NTLA as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of NTLA
On Monday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock fall -3.10% to $23.76. Over the last five days, the stock has gained 15.68%. Intellia Therapeutics Inc shares have risen nearly 34.62% since the year began. Nevertheless, the stocks have risen 103.77% over the past one year.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2025-09-30, growing by 2.0 million shares to a total of 29.74 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 27.74 million shares. There was a rise of 6.73%, which implies that there is a positive sentiment for the stock.
